Trinidad and Tobago: OilWell Cannabis Houston Delivers 16,590mg 7-Cannabinoid THCa RSO Sublingual Oil with 553mg/mL Potency & 1,500mg Patient-Controlled THCa-to-THC Conversion for Up to 1,405mg Total Activated Delta-9 THC, ABC13-Featured & COA-Backed from Bentley’s 10-Year Miracle Legacy, Farm Bill-Compliant International Shipping

OilWell Cannabis Rick Simpson Oil: The Complete Trinidad and Tobago Guide

Understanding Rick Simpson Oil: From Nova Scotia to Trinidad and Tobago

Who Was Rick Simpson?

Rick Simpson wasn’t a doctor, scientist, or medical professional. He was a power engineer from Amherst, Nova Scotia — a tradesman who found himself in the same position many people in Trinidad and Tobago face when conventional medicine falls short. His story resonates across our islands because we’ve all seen friends, family, or neighbors struggling with conditions that standard treatments can’t touch.

In 1997, while working at a hospital in Moncton, Simpson suffered a serious head injury from a scaffolding fall. The aftermath included persistent tinnitus and post-concussion symptoms that his doctors couldn’t resolve. The medications either failed to help or made things worse. When he asked his physician about cannabis, the request was refused. That moment — being told “no” by a medical professional despite witnessing benefits — is a frustration many Trinidadians and Tobagonians know intimately, especially those navigating our own healthcare system’s limitations.

Simpson’s interest deepened after learning about a 1974 NIH-funded study at the Medical College of Virginia, where THC reportedly slowed tumors in mice. While that research never translated to human cancer trials, it became the spark that lit the RSO movement.

The pivotal moment came in 2003 when Simpson claimed that three bumps on his arm, diagnosed as basal cell carcinoma, disappeared after he applied concentrated cannabis oil directly to them. No independent medical verification was ever published. No biopsy confirmation exists in any peer-reviewed source. But this personal experience became the origin story of Rick Simpson Oil and the foundation of a global movement that eventually reached Trinidad and Tobago’s shores.

Important context: Simpson’s account is personal testimony, not medical evidence. The absence of clinical documentation means these events cannot be evaluated as scientific proof. They are, however, historically significant as the catalyst for worldwide interest in concentrated cannabis oil.

The Crusade: How RSO Spread Globally

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free to cancer patients and others in his community. He helped dozens with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, and insomnia — conditions that affect people across Trinidad and Tobago every day.

His story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film became one of the most widely shared cannabis advocacy films of its era. For many people worldwide — including many in Trinidad and Tobago — Run From The Cure was their first introduction to concentrated cannabis oil as medicine.

Simpson’s advocacy brought him into conflict with Canadian law. The Royal Canadian Mounted Police raided his property in 2005 and again in 2009. He was charged with cultivation, possession, and trafficking. Facing continued legal pressure, he eventually left Canada for Europe, living in Croatia and later the Netherlands, where he continued his advocacy from abroad.

In 2012, he published Phoenix Tears: The Rick Simpson Story and maintained phoenixtears.ca as his information platform.

Throughout his career, Simpson maintained that cannabis oil — particularly high-THC oil made according to his method — could cure cancer and many diseases. He framed his work as a fight against institutional suppression by pharmaceutical companies and government agencies.

Important context: Simpson’s conspiratorial framing is noted here without endorsement. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding RSO’s cultural significance. The evidence-based assessment follows below.

The Traditional RSO Protocol: Simpson’s 60-Gram Program

Simpson’s core recommendation was a structured oral protocol delivering 60 grams of concentrated oil over approximately 90 days. For Trinidad and Tobago residents researching “RSO dosing protocol” or “how much RSO to take,” here’s exactly what Simpson described.

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over roughly 90 days. Simpson considered this the minimum for a serious cancer treatment course.

Titration Schedule

• Week 1: Begin with a dose the size of half a grain of rice — roughly 10-15mg of oil — taken three times daily. Total daily intake: approximately 30-45mg.
• Weeks 2-5: Double the dose approximately every four days to build tolerance gradually. By the end of this period, reach approximately 1 gram (1,000mg) of oil per day, divided into three doses of roughly 333mg each.
• Weeks 5-12: Maintain the full dose of approximately 1 gram per day until all 60 grams are consumed.

Administration Methods

• Oral (primary): Place dose directly under the tongue or swallow. Simpson considered this the most important route for systemic absorption.
• Topical (secondary): For skin cancers and external lesions, apply oil directly to the affected area, cover with a bandage, and change every 3-4 days. Combined with oral dosing for skin cancers.
• Inhalation (not recommended as primary): Simpson acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that oral route was necessary for sustained, high-dose exposure.

Tolerance and Psychoactive Effects

• Simpson maintained that patients develop significant THC tolerance within 3-4 weeks.
• He considered psychoactive effects a minor, temporary side effect and urged patients not to let the “high” discourage continuation.
• Recommended initial doses at night to sleep through the most intense effects.
• Warned against driving or operating machinery during titration.

Post-Protocol Maintenance

After completing the 60-gram course, Simpson recommended 1-2 grams of oil per month as ongoing maintenance.

Dietary and Lifestyle Recommendations

Simpson also advocated reducing sugar intake, avoiding processed foods, and improving overall nutrition — though this advice was secondary to the oil protocol.

Important Context for Evaluating This Protocol

This protocol was designed by one person based on personal experience. It was not developed through clinical trials, dose-finding studies, or formal research. Critical points for Trinidad and Tobago readers:

• No controlled trial validation. No published randomized controlled trials or well-documented case series evaluate this specific 60-gram/90-day protocol for any cancer type or condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content varied widely.
• Very high THC exposure. At peak dosing (1 gram of 60-90% THC oil daily), patients consumed approximately 600-900mg of delta-9 THC per day. For context, FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5-20mg per day.
• Real risks at these doses. Consuming 600-900mg of THC daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [1][13][14][15].
• Oncology context. Patients with active cancer are medically complex. Using unregulated, unstandardized cannabis oil as primary treatment — potentially in place of proven therapies — introduces harm beyond the oil itself.

What Is Traditional RSO?

Traditional RSO refers to the specific oil Simpson made. It was defined by his method, not lab specifications.

Source Material: High-THC, indica-dominant cannabis strains with no standardization.

Extraction Solvent: Naphtha (petroleum-based) or 99% isopropyl alcohol. Neither is food-grade. Naphtha may contain benzene, toluene, and other toxic compounds.

Extraction Process: Cannabis placed in bucket, covered with solvent, agitated, filtered through cheesecloth, evaporated in rice cooker at 60-80°C, final oil transferred to syringes.

Appearance: Nearly black, thick, tar-like oil with strong cannabis odor and possible solvent-residual smell.

Cannabinoid Profile: Fully decarboxylated, THC-dominant (60-90% estimated), with minor cannabinoids at uncontrolled natural ratios. No lab verification.

Terpene Content: Minimal to none. Solvent and high-heat evaporation destroyed terpenes.

Standardization and Testing: None. Every batch differed based on plant material, growing conditions, solvent purity, and technique.

Residual Solvent Risk: Significant. Incomplete purging leaves potentially harmful residues. Modern extraction uses food-grade ethanol or CO₂ to address this.

Simpson’s Claims vs. The Evidence Record

Rick Simpson made expansive claims: RSO could cure cancer, diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and more. He was adamant and consistent.

What Simpson Was Not

He was not a scientist, physician, pharmacologist, or researcher. He had no formal medical training, never designed or published a clinical trial, never submitted results to peer review. His evidence base consisted of personal experience, self-reported outcomes, and informal testimonials — with no controls, verification, or blinding.

What The Preclinical Literature Shows

• In vitro studies show THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines .
• Animal studies show some tumor-growth inhibition .
• These findings generate scientific interest but have not translated to proven human cancer cures.

What The Preclinical Literature Does Not Show

• No human clinical trial has demonstrated that RSO or any cannabis oil cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been exploratory and have not produced results supporting cure claims .

Institutional Positions

• U.S. National Cancer Institute: Acknowledges cannabinoids have been studied for potential anticancer effects but does not endorse cannabis or cannabis oil as cancer treatment .
• U.S. Food and Drug Administration: Has not approved any cannabis plant product for cancer treatment. Only FDA-approved cannabinoid products are for specific indications: Epidiolex (CBD) for certain seizure disorders, dronabinol/nabilone for chemotherapy nausea and AIDS-related wasting [1].
• Health Canada: Has never approved RSO or cannabis oil as cancer cure.
• NCCIH: Strongest cannabinoid evidence is for rare epilepsies, chemo nausea, and HIV/AIDS appetite — not cancer cure [1].

What Simpson Got Right

He drew attention to cannabinoids as serious biomedical research when most ignored it. His advocacy helped create conditions for legal cannabis industry and research infrastructure. He brought concentrated cannabis oil to widespread awareness. The term “RSO” remains the most recognized name for full-spectrum cannabis extract.

What He Overstated

The leap from preclinical signals to cancer cure was not supported by human evidence then and is not supported now. Encouraging patients to rely on RSO as primary treatment in place of proven oncologic therapies carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in alternative medicine.

The Legacy of Rick Simpson and Modern RSO

The term “RSO” is now used broadly and loosely across the legal cannabis industry. Many products labeled RSO bear little resemblance to Simpson’s original. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract in syringe format.

Simpson has been critical of commercial products departing from his method and philosophy. He gave oil away for free and urged DIY production. The modern cannabis industry has commercialized, standardized, and regulated what he distributed freely.

This philosophical tension is real. Simpson’s model was anti-commercial. Whether modern evolution represents improvement (quality control, testing) or betrayal (profit extraction) depends on perspective. The cannabis community remains divided.

What is not disputed: modern RSO has evolved substantially, and those changes matter for the formulas in this document.

Traditional RSO vs. Modern Formulated RSO

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not performed	Full panel testing
Residual solvents	Significant risk	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known content (553mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as distinct ingredient (1,500mg)
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s Formulas Diverge From Traditional RSO

OilWell’s formulations are deliberate, evidence-motivated departures that solve problems limiting Simpson’s original vision:

Multi-cannabinoid approach. Traditional RSO relied on whatever single strain was available. OilWell includes seven cannabinoids because entourage-effect literature suggests potential benefit from diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

Terpene preservation and addition. Traditional RSO had essentially no terpenes. OilWell includes live terpenes at 5% with a specific seven-terpene profile because terpene bioactivity is plausible at the preclinical level, even if human clinical confirmation remains limited [20][21][23][24][25][26][27][28][29].

THCa as separate ingredient. Traditional RSO fully decarboxylated everything. OilWell’s sublingual formula includes THCa at 1,500mg as a distinct ingredient because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC [12].

Reduced delta-9 THC dominance. Traditional RSO was 60-90% delta-9 THC. OilWell’s sublingual formula uses only 90mg delta-9 THC total while distributing the remaining content across CBD (4,500mg), CBG (3,000mg), delta-8 THC (6,000mg), THCa (1,500mg), CBN (750mg), and CBC (750mg). This reflects broader cannabinoid research rather than single-compound dominance.

Product format innovation. Simpson envisioned only oral oil. OilWell offers both 30mL sublingual oil and 1-gram vape cartridge, each with format-specific formulations acknowledging that different delivery routes have different pharmacokinetic profiles [14].

Solvent Safety and Extraction Evolution

Traditional RSO used naphtha or isopropyl alcohol — neither food-grade. Naphtha may contain benzene, toluene, and other toxic compounds. Incomplete purging leaves harmful residues.

Modern extraction uses food-grade ethanol or supercritical CO₂, allowing much more complete solvent removal. Finished products can be tested for residual solvents using validated analytical methods. This is one of the most straightforward improvements the modern regulated cannabis industry has made over traditional RSO.

This evolution connects directly to product-quality discussions in the GENERAL KNOWLEDGE section, which emphasizes that product quality matters as much as molecule identity [1][10][11][14].

The Decarboxylation Question

Traditional RSO was fully decarboxylated. The heat of solvent evaporation (60-80°C) converted essentially all THCa into delta-9 THC. This meant acidic cannabinoids were lost as distinct compounds.

OilWell’s sublingual formula deliberately preserves THCa at 1,500mg. This is an intentional formulation choice informed by the THCa evidence profile, which notes that THCa itself does not produce psychoactive effects but has potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12].

Terpene Loss in Traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points (21-157°C). Traditional RSO destroyed terpenes through solvent extraction and high-heat evaporation.

OilWell’s formulas specify live terpenes at 5% with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each terpene has its own evidence profile in the GENERAL KNOWLEDGE section. The entourage-effect literature provides theoretical framework for why preserving terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof remains limited [20][29].

Evidence Standards Then and Now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. Cannabis was illegal. There was no regulatory framework, no standardized testing, no legal pathway for clinical research, no peer-reviewed journals dedicated to cannabis therapeutics. The underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected those constraints. His evidence was anecdotal. His production was unstandardized. His claims were untested.

This document takes a fundamentally different approach. The GENERAL KNOWLEDGE section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews, then institutional summaries, then preclinical literature [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. Where Simpson relied on personal testimony, this document relies on published literature.

Simpson’s Protocol vs. Modern Dosing Considerations

Simpson’s 60-gram/90-day protocol was designed around crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison to a modern, standardized, multi-cannabinoid formulation is not straightforward.

Key differences:

• Cannabinoid concentration: OilWell’s sublingual formula delivers 553mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios: Simpson’s oil was 60-90% delta-9 THC. OilWell’s formula distributes 16,590mg across multiple compounds.
• Terpene presence: Simpson’s oil had no terpenes. OilWell includes live terpenes at 5%.
• Delta-9 THC exposure: Simpson’s protocol delivered ~600-900mg delta-9 THC daily. OilWell’s sublingual formula contains only 90mg delta-9 THC in the entire 30mL bottle (3mg per mL).

For Trinidad and Tobago readers: Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by per-compound evidence in the GENERAL KNOWLEDGE section and by responsible titration principles that account for each cannabinoid’s safety profile. This section does not provide specific dosing recommendations — that work requires its own development process.

How OilWell Cannabis Came to Serve Trinidad and Tobago

The OilWell Story: From McAllen to Houston to Your Doorstep

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. But our story begins far from Texas — just as it begins far from Trinidad and Tobago. Colin grew up in McAllen, Texas, right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. Reynosa is an industrial hub plagued by violence and cartel activity. McAllen is a city of contrasts — vibrant culture and a thriving retail sector, yet deeply affected by poverty and limited opportunities outside of retail and healthcare.

Colin’s childhood was marked by exposure to both opportunities and challenges. By sixteen, he was involved in transporting items across the border for various groups. A lot of his best friends have been killed or are in prison because of associated dangers. He has faced every form of violence imaginable, both in the streets and across the border. By sixteen, one way or another, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths. He focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination — deep cannabis plant knowledge plus medical-grade technical precision — would eventually define OilWell’s approach.

And then came Bentley.

Bentley’s Story: Where It All Began

Bentley was more than a pet — he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up wasn’t an option. In a desperate search for alternatives, a rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

That question exposed a blind spot that would become OilWell’s mission. Colin learned to create CBD golden paste — a specialized cannabinoid formula for pets. It was not a cure, but it was hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play.

From paralyzed and facing euthanasia to fetching his ball. This was not placebo — dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced:

• Neurodegeneration led to understanding CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection.
• Dementia led to CBC’s role in neurogenesis.
• Glaucoma led to THC’s CB1 agonism for intraocular pressure reduction.
• Crippling arthritis led to multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical. Pharmaceutical precision mattered — Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into cannabis beyond getting high. It became a mission to create real solutions that alleviate pain and suffering — not just for pets, but for people. Bentley’s story is the foundation of OilWell Cannabis, driving our commitment to quality, innovation, and compassionate care.

Colin’s Personal Journey: PTSD, Benzo Addiction, and Peace

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — notoriously difficult and dangerous — using the cannabinoid knowledge he developed keeping Bentley alive.

The Peace Gummies formula was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Over time, the therapeutic benefits Colin first discovered through Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

Media Recognition: Why Trinidad and Tobago Can Trust OilWell

Between September 2019 and April 2023, ABC13 Houston — the ABC affiliate serving America’s fourth-largest city — featured Colin Valencia and OilWell Cannabis in seven distinct news segments. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or breadth.

When ABC13 needed to explain a new cannabis product, it called Colin. When a state agency reversed course on Delta-8 legality overnight, it called Colin. When a sitting president announced marijuana pardons and the station needed someone who had personally lived with a cannabis conviction, it called Colin. When the station wanted to tell the story of a growing industry on 4/20, it was Colin’s hemp field and voice that anchored the report.

September 15, 2019: The Foundation

In our first ABC13 feature, Colin established OilWell’s philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

That 2019 quote is the seed of everything OilWell would become: open-source formulas, evidence-based research documentation, refusal to make unsupported claims.

March 22, 2021: The Therapy Dimension

Tom Abrahams returned to OilWell, establishing Colin’s role as ecosystem builder helping other entrepreneurs. Colin’s quote — “Pain comes in a lot of different forms” — went deeper into the therapeutic dimension, positioning OilWell at the intersection of Texas innovation and federal momentum.

May 24, 2021: Radical Honesty

Steve Campion’s investigative feature on Delta-8 THC included Colin’s iconic exchange: “Maybe you want to get high.” That uncensored honesty on mainstream television — with the expletive preserved by the network — became one of Colin’s most iconic media moments. The piece balanced Colin’s unapologetic stance with medical caution and regulatory advocacy, documenting federal ambiguity that allowed the market to exist.

August 20, 2021: Community Health Action

OilWell gave away approximately $35,000 in product (1,000 caviar pre-rolls) to encourage COVID-19 vaccination. Hosted at HydroShack Hydroponics, the giveaway included coordination with the city of Houston to help more people get vaccinated, with no political strings attached.

October 19, 2021: Ethical Leadership During Crisis

When Texas DSHS classified Delta-8 as Schedule I overnight, Shelley Childers found that Colin had already removed all Delta-8 products from shelves — proactively, before enforcement, and before most of the industry knew the change happened. Colin tried to spread the word to other operators unknowingly shipping what had become Schedule I narcotics.

Zachary Maxwell’s context — veterans with PTSD, the $50 million Texas market, felony penalties for a single vape cartridge — made stakes viscerally clear. Texas DSHS told ABC13 Delta-8 “has always been illegal” but couldn’t explain how the market had been “allowed to publicly blossom and thrive while being considered illegal.”

The willingness to absorb major revenue loss, act ethically ahead of enforcement, and position the company as expert guide rather than victim — that is OilWell’s character.

October 7, 2022: Personal Stakes Revealed

Nick Natario’s feature opened with OilWell’s CBD vending machine debut, then revealed Colin has previously faced charges for marijuana possession. That personal history transforms the entire media record. Every quote about therapy, education, not selling snake oil — all carry additional weight when you understand the person saying it has personally experienced cannabis criminalization.

April 21, 2023: The Renaissance Framing

The most recent feature, published the day after 4/20, showed Colin growing hemp on camera, explaining: “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.” Nico Richardson’s comparison (Texas 10,000 active patients vs. Florida 700,000) and the $3.7 billion tax revenue figure from legal states gave the story national scope.

The Through-Line: Consistency, Action, and Authenticity

These seven features tell a story no single article could capture:

Consistency across years. Colin appeared on ABC13 in 2019, 2021 (four times), 2022, and 2023. Through every shift in Texas law, ABC13 returned to Colin as primary source.

Breadth of expertise. Features span business reporting, consumer health education, product investigation, legal analysis, political commentary, and community health advocacy.

Community action. The COVID vaccine giveaway and proactive Delta-8 removal are documented evidence of community-first philosophy.

Personal stakes. The revelation of cannabis conviction history shows Colin is not an outside entrepreneur who saw opportunity — he is someone who lived consequences and built a legal business to prove the industry could operate with integrity.

Evolution of language. From “OilWell CBD, a local wholesaler” (2019) to “industry authority” (2021) to “Renaissance” framer (2023), the media record tracks growth of both business and founder’s public role.

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin Valencia as the most credible, quotable, accessible voice in Houston’s legal cannabis industry. That is recognition that cannot be purchased — it can only be earned.

The Science Behind OilWell’s RSO: Evidence for Trinidad and Tobago

Research Method and Evidence Weighting

This section prioritizes sources in order: human clinical evidence, systematic reviews and meta-analyses, NIH and institutional summaries, then preclinical literature when human data are sparse. This weighting matters because the evidence base is uneven. CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes depend more on reviews, animal work, and in vitro pharmacology [1]-[29].

Institutional Baseline from NIH and Related Sources

• NCCIH states strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. Only modest evidence exists for chronic pain and multiple-sclerosis symptoms. Many claimed uses remain early-stage [1].
• FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC drugs have specific approvals [1].
• Safety concerns repeatedly highlighted: impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns [1].

Cannabinoid Profiles

CBD

Evidence profile: Strongest human evidence in this formula, especially as purified product [1]-[6].

• Seizure disorders: Purified CBD has the most credible human evidence, acknowledged by institutional and peer-reviewed literature [1][2].
• Anxiety: 2024 systematic review and meta-analysis of 316 participants reported statistically significant anxiolytic signal, but authors stressed clinical sample remains limited [3].
• Pain: 2024 systematic review concluded pain literature is promising but heterogeneous, with trial quality limiting confidence in broad analgesic claims [4].
• Sleep: 2023 insomnia review found literature methodologically weak, with many studies relying on nonvalidated subjective measures [5].
• Safety: 2023 systematic review found real signal for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH also flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions [1].
• Bottom line: CBD is most evidence-developed nonintoxicating cannabinoid, but strong evidence is concentrated in few specific indications rather than broad wellness claims [1]-[6].

CBG

Evidence profile: Mostly review-level and preclinical; human evidence sparse [7][8].

• Pharmacology: CBG is biosynthetic precursor to several major cannabinoids with distinct pharmacology interacting with cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A-related signaling [7].
• Potential areas: Review literature discusses neurologic disorders, inflammatory bowel disease, antibacterial activity — primarily pharmacology-led hypotheses or preclinical findings rather than mature human conclusions [7][8].
• Caution: 2021 pharmacology review notes CBG is already sold commercially while evidence base remains thin, meaning claims frequently outrun science [7].
• Bottom line: CBG is serious research topic but should be described as promising minor cannabinoid with limited clinical validation rather than proven therapeutic [7][8].

Delta-8 THC

Evidence profile: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC [9]-[11].

• Comparative pharmacology: 2022 review concluded delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is partial CB1 agonist with cannabimimetic activity, but appears less potent than delta-9 THC, likely due to weaker CB1 affinity [9].
• Public health: 2023 scoping review found delta-8 evidence base dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. Review noted reports of adverse consequences and emphasized regulatory and product-quality concerns [10].
• Manufacturing context: 2024 chemistry and pharmacology review reinforces commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product-byproduct and lab-testing questions matter [11].
• Bottom line: Delta-8 THC should be treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize [9]-[11].

THCa

Evidence profile: Important chemically and formulation-wise, but low on direct human therapeutic evidence [12].

• What it is: THCa is acidic precursor of THC and may represent large share of THC-related content in raw plant material. Key formulation issue: THCa decarboxylates into THC during heating and can change over time during storage and processing [12].
• Psychoactivity: Major review stresses THCa itself does not produce psychoactive effects associated with THC in humans, but distinction only holds if molecule stays in acidic form and is not substantially decarboxylated [12].
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes [12].
• Bottom line: THCa is best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa needs to account for possible conversion into THC [12].

Delta-9 THC

Evidence profile: Strongest human evidence of psychoactive cannabinoids listed here, but also clearest adverse-effect burden [1][13]-[15].

• Institutionally supported: NCCIH identifies THC-containing medicines as relevant to chemotherapy nausea/vomiting, HIV/AIDS appetite/weight loss, and some multiple-sclerosis- and pain-related outcomes, while stressing many other uses remain uncertain [1].
• Pain evidence: 2022 systematic review found cannabis-based products with high THC content or comparable THC:CBD ratios may provide short-term pain benefit, but also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events [13].
• Pharmacokinetics: Classic review literature remains useful: inhaled THC produces effects within seconds to minutes, peaks roughly within 15-30 minutes, and tapers over few hours; oral THC has later onset, later peak, and longer duration [14].
• Mental health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with concerning signals for anxiety and depression in nontherapeutic settings [15].
• Broader safety: Institutional and review literature describe anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns [1][14][15].
• Bottom line: Delta-9 THC has legitimate therapeutic relevance in some settings, but carries clearest intoxication, psychiatric, and dose-related safety liabilities in this document [1][13]-[15].

CBN

Evidence profile: Weak human evidence; marketing has clearly moved ahead of data [12][16][17].

• What marketed for: Sleep and sedation. Reputation is widespread, but clinical support far thinner than market suggests [16][17].
• Best review for sleep claim: 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims [16].
• Broader sleep literature: 2024 updated review concluded overall cannabinoid sleep research still does not match scale of real-world use, and need for better-designed, adequately powered trials remains substantial [17].
• Chemical context: Review literature on THCa notes THC can further degrade toward CBN under certain conditions, explaining why CBN is often discussed in aging or oxidized cannabis chemistry contexts [12].
• Bottom line: CBN is clearest example where cultural reputation is stronger than current clinical evidence base [16][17].

CBC

Evidence profile: Emerging, intriguing, still overwhelmingly preclinical or review-based [18][19].

• Pharmacology: 2024 focused review argues CBC has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, highlighting antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets [18].
• Older literature: Review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims [19].
• Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety [18].
• Bottom line: CBC belongs in category of scientifically credible minor cannabinoids that deserve more research, not in category of already-validated clinical actives [18][19].

Terpene Profiles

Limonene

Evidence profile: Largely review and preclinical, with useful safety literature [20]-[22].

• Potential activity: 2021 review describes limonene as multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities, but overwhelming share of claims comes from nonhuman or non-cannabis literature [21].
• Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing literature [22].
• Bottom line: Limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22].

Myrcene

Evidence profile: Mostly preclinical, very limited human evidence [20][23].

• Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties and discusses possible mechanisms, but explicitly states human studies are lacking [23].
• Interpretation caution: Myrcene is often invoked as proven sedating terpene that explains couch-lock or sleep effects. That is stronger claim than human evidence currently supports [20][23].
• Bottom line: Myrcene is plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof [23].

Caryophyllene

Evidence profile: Among most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical [24].

• Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist, unusual and especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms [24].
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective actions repeatedly discussed, but human clinical confirmation remains limited [24].
• Bottom line: Beta-caryophyllene is arguably strongest candidate for terpene with cannabinoid-system significance, but still should not be described as clinically proven for outcomes commonly attributed to it [24].

Pinene

Evidence profile: Promising preclinical literature, weak human clinical confirmation [20][25].

• Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasized evidence is mostly preclinical and well-designed clinical trials are lacking [25].
• Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25].
• Bottom line: Pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25].

Linalool

Evidence profile: Substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].

• Research summary: Linalool repeatedly discussed in relation to stress, mood, brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing lack of robust human trials [25].
• Additional literature: Separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but this remains translational rather than definitive clinical story [26].
• Safety note: As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature [22].
• Bottom line: Linalool is scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].

Humulene

Evidence profile: Translationally interesting, but still early [20][27].

• Scoping-review findings: 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].
• Interpretation caution: Those findings are valuable for hypothesis generation, but they do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27].
• Bottom line: Humulene is one of more interesting terpene research targets, but remains far from clinically settled [27].

Terpinolene

Evidence profile: One of least clinically characterized terpenes in this file [20][28].

• Systematic-review findings: 2021 terpinolene review screened 2,449 records and included 57 studies, concluding terpinolene has range of reported biological effects but evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials [28].
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects [20].
• Bottom line: Terpinolene is biologically interesting, but among listed terpenes remains especially underdeveloped clinically [20][28].

Research Limits and Interpretation

• Evidence base is highly uneven. CBD and delta-9 THC can support most detailed human-facing statements; rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. Common error is letting evidence from one category stand in for another.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means claims around them often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products [1][10][11][14].
• For THCa in particular, chemistry is destiny: storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC [12].

Common Overstatements to Avoid

• Overstatement: CBN is clinically proven sleep cannabinoid.
  More accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17].
• Overstatement: Myrcene is proven human sedative that reliably explains couch-lock.
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23].
• Overstatement: Terpenes in general have proven entourage effects in patients.
  More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure [12].
• Overstatement: Delta-8 THC is safe because it is hemp-derived.
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].

Practical Takeaways for Trinidad and Tobago Readers

• Most evidence-developed actives in these formulas are CBD and delta-9 THC.
• Delta-8 THC is not trivial or purely mild ingredient; it is psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted same way in raw, gently handled, and heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC.
• Listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

OilWell’s RSO Formulas: Exact Specifications

RSO Sublingual Oil

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30mL bottle (1 fl oz)
• Active cannabinoids per mL: 553mg
• Carrier: Organic MCT oil
• Dosing: Graduated dropper for precise 0.1mL increments
• Onset: 15-45 minutes (sublingual)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (partially bypasses first-pass liver metabolism)
• Approximate doses per bottle: 40-60 depending on serving size

RSO Vape Cartridge

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1-gram cartridge
• Battery compatibility: 510-thread universal
• Onset: 1-2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable based on inhalation technique)
• Auto-decarboxylation: THCa converts instantly at vaping temperature (400-450°F)

Terpene Profile (Both Products)

• Limonene: Citrus-bright
• Myrcene: Musky, earthy
• Caryophyllene: Pepper/spice
• Pinene: Forest-fresh
• Linalool: Floral, lavender
• Humulene: Earthy, woody
• Terpinolene: Piney, fruity, sparkling

When to Use Each Format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability/discretion	Vape	Compact, no measuring
Precise dosing control	Sublingual	Graduated dropper (0.1mL)
Daytime non-psychoactive	Sublingual (raw)	THCa stays inactive, zero impairment
Nighttime psychoactive	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

How Trinidad and Tobago Can Access OilWell RSO

Legal Framework: What You Need to Know

OilWell’s RSO products are crafted under the 2018 U.S. Farm Bill, which legalized hemp-derived products containing less than 0.3% delta-9 THC by dry weight. Our RSO Sublingual Oil contains only 90mg delta-9 THC in the entire 30mL bottle — 3mg per mL — well under the 0.3% threshold. All cannabinoids are hemp-derived.

For Trinidad and Tobago customers: This product is legal under U.S. federal law and in most jurisdictions. However, you are responsible for understanding and complying with Trinidad and Tobago’s local laws regarding hemp-derived products. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility.

The THCa Advantage: Patient-Controlled Potency

Traditional RSO was always fully decarboxylated — always psychoactive. OilWell’s sublingual formula contains 1,500mg THCa in its acidic, non-psychoactive form, creating three usage options:

Option 1 — Raw, no heat: All 1,500mg stays as THCa — completely non-psychoactive. Provides anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. Compatible with work, driving, and daytime use with zero impairment.

Option 2 — Fully activated, home decarboxylation: Heating oil at 260°F (125°C) for 45-60 minutes in oven-safe glass container converts 1,500mg THCa into approximately 1,315mg delta-9 THC. Combined with existing 90mg delta-9 THC, this yields ~1,405mg total delta-9 THC — psychoactive potency comparable to traditional illegal RSO, 100% legally, because decarboxylation occurs at your discretion after purchase. You may transfer a controlled portion to a second oven-safe container, decarboxylating only what you intend to use and preserving remainder in raw THCa form.

Option 3 — Vape, auto-decarboxylation: Vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. Fastest-onset RSO delivery method available.

Conversion chemistry: 1mg THCa = 0.877mg delta-9 THC after decarboxylation, reflecting loss of CO₂ molecule.

This design puts potency decision entirely in your hands — aligning with Simpson’s principle that patients should control their own medicine, but implementing it through actual product chemistry.

Shipping to Trinidad and Tobago: What to Expect

OilWell ships nationwide across the United States and internationally to verified customers. For Trinidad and Tobago:

International Shipping Process:

• All packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes
• Minimum flat-fee shipping applies; excessive international shipping costs are billed to customer
• You are responsible for verifying legality in Trinidad and Tobago and accepting all customs and legal risk
• Discreet packaging with no cannabis branding visible
• Temperature-stable packaging for tropical climate shipments
• Tracking provided for all orders
• Signature-required option available

Contact for International Orders:

• Phone: (832) 416-2816
• Email: [email protected]
• Website: OilWellCBD.com

The significance of international access cannot be overstated. Rick Simpson could not ship his oil anywhere — it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Port of Spain, a chronic pain sufferer in San Fernando, or a veteran in Scarborough can now potentially access the same clinical-strength multi-cannabinoid RSO formula that Houston residents receive. OilWell built a product that can move across borders legally — completing a piece of Simpson’s vision that prohibition made impossible.

OilWell’s PANDEM1C SEO technology — proprietary system with 14 million distinct geopolitical locations in database and over 300 AI models — drives organic search visibility across six continents, making our products discoverable to international patients searching for RSO in their own language.

Pricing and Value for Trinidad and Tobago

RSO Sublingual Oil: $129.99 USD for 30mL containing 16,590mg total cannabinoids
RSO Vape Cartridge: $49.99 USD for 1-gram cartridge

For Trinidad and Tobago customers considering purchase, these prices reflect:

• 16,590mg total cannabinoids across seven compounds vs. typical CBD products with 1,000mg single cannabinoid
• Laboratory testing for potency, terpenes, pesticides, heavy metals, residual solvents, microbial contaminants
• Open-source transparency — you receive exact formula, not proprietary blend
• International shipping capability with full documentation
• Patient-controlled potency — one product serves both non-psychoactive and psychoactive needs

If cost is prohibitive, remember: OilWell publishes complete formulas publicly. You can source individual cannabinoid distillates and isolates and make your own version. This is direct echo of Rick Simpson’s original ethos — adapted for modern cannabinoid marketplace.

Condition-Specific Usage Context for Trinidad and Tobago

Important disclaimer: Following contexts are informed by cannabinoid research cited in GENERAL KNOWLEDGE section and OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not substitute for professional medical care. These products have not been evaluated by Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult qualified healthcare provider before using cannabinoid products, especially if you have medical condition, are taking medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support

For Trinidad and Tobago cancer patients navigating treatment at Port of Spain’s hospitals or regional cancer centers:

• Pre-chemo: 0.5-1.0mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0mL sublingual before bed (delivers 25-50mg CBN)

Evidence context: delta-8 THC antiemetic evidence [9], delta-9 THC nausea and vomiting evidence [1][13], CBD anxiolytic buffering [3]

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

For Trinidad and Tobago residents dealing with chronic pain in humid tropical climate where inflammation can be particularly challenging:

• Daytime: 0.3-0.5mL raw sublingual — provides anti-inflammatory cannabinoid exposure without psychoactive impairment, allowing you to work, drive, and function
• Nighttime: 0.5-1.0mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep Support

For Trinidad and Tobago residents struggling with sleep in warm climate or dealing with stress-related insomnia:

• Before bed: 1.0-2.0mL sublingual
• At 2.0mL, delivers 50mg CBN — dosage level investigated in 2024 sleep literature
• At 1.0mL, delivers 25mg CBN — above 20mg threshold associated with reduced sleep disturbance in published research

Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature

Anxiety and Stress

For Trinidad and Tobago residents managing work stress, family pressures, or anxiety in fast-paced island economy:

• Daytime functional relief: 0.3mL raw sublingual — CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0mL sublingual — full cannabinoid profile including CBN for sleep architecture

Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

General Titration Principle for Trinidad and Tobago Users

Start low, go slow. Begin with 0.25-0.5mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Making OilWell’s RSO Work for You in Trinidad and Tobago

Open-Source Formulas: Transparency You Can Verify

OilWell publishes complete formulas publicly — every cannabinoid, every milligram, every percentage. If you cannot afford our products, you can source ingredients and make your own. This is direct echo of Rick Simpson’s original ethos: he gave his oil away for free and taught people how to make it. He never patented his method, never charged patients. OilWell adapted that ethos for modern marketplace: we sell professionally manufactured, lab-tested, standardized product for those who want it, and we publish complete recipe for those who want to make it themselves.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The Original Open-Source Formula: CBD Golden Paste for Pets

Before RSO, there was Bentley’s golden paste. We published this recipe years before publishing RSO formulas, demonstrating that open-source ethos is foundational behavior, not marketing strategy.

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on size and needs; consult veterinarian)

Instructions:

1. Mix turmeric and water in saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes). Add more water if too thick.
2. Add coconut oil and pepper. Stir until thoroughly mixed.
3. Cool, transfer to jar with lid, refrigerate up to two weeks.
4. Add CBD oil to paste before giving to pet, adjusting dosage based on weight and health needs. Start low and increase gradually.
5. Mix small amount with pet’s food once or twice daily. Monitor changes and consult veterinarian if concerns arise.

For Trinidad and Tobago pet owners: This recipe uses ingredients available at local markets and health food stores. It’s free, it’s useful, and it demonstrates OilWell’s character better than any marketing copy.

Why Seven Cannabinoids? The Bentley Lesson

Bentley’s evolving conditions REQUIRED multi-cannabinoid formulation. Single cannabinoids were not enough. This is why OilWell’s RSO has SEVEN cannabinoids instead of one or two. It wasn’t a marketing decision — it was born from necessity. The seven-cannabinoid formula is a decade of love turned into science.

The seven-cannabinoid synergy:

• CBD (4,500mg): Anti-inflammatory, anxiolytic, neuroprotective
• CBG (3,000mg): Neuroprotection, anti-inflammatory, antibacterial potential
• Delta-8 THC (6,000mg): Pain relief, anti-nausea, psychoactive but less potent than delta-9
• THCa (1,500mg): Anti-inflammatory via COX-2, neuroprotective via PPARγ (non-psychoactive when raw)
• Delta-9 THC (90mg): Entourage contribution, minimal psychoactive load
• CBN (750mg): Sleep support (emerging evidence)
• CBC (750mg): Neurogenesis, anti-inflammatory (preclinical promise)

This combination addresses multiple pathways simultaneously — something single-cannabinoid approaches cannot achieve. For Trinidad and Tobago residents dealing with complex health challenges, this multi-pathway approach mirrors how traditional Caribbean medicine often combines multiple herbs for synergistic effect.

Final Thoughts for Trinidad and Tobago: Accessibility, Integrity, and Hope

OilWell Cannabis is more than a brand — it is a promise to our customers that we will always strive to deliver the best, most thoughtful cannabis products available. We are not here to follow trends. We are here to set them. And as we continue to grow, our focus remains on maintaining the same level of integrity, creativity, and commitment that defined us from the day Bentley got up, walked across the room, and brought his ball to play.

For Trinidad and Tobago residents searching for “RSO near me,” “buy Rick Simpson Oil Trinidad and Tobago,” or “cannabis oil for cancer Trinidad and Tobago,” we offer something unique:

1. Transparency: Exact formulas published, nothing hidden
2. Quality: Laboratory-tested for potency, terpenes, pesticides, heavy metals, residual solvents, microbial contaminants
3. Flexibility: One product serves as both non-psychoactive anti-inflammatory (raw) and full-potency psychoactive medicine (decarbed)
4. Access: International shipping with full documentation
5. Evidence: Every claim anchored to peer-reviewed research, not hype
6. Honesty: We tell you what works, what doesn’t, and what remains uncertain

We understand that in Trinidad and Tobago, healthcare access can be challenging, specialist wait times can be long, and pharmaceutical options don’t work for everyone. We understand that island life — while beautiful — comes with unique stressors: hurricane season anxiety, economic pressures, and limited access to certain treatments.

Our products are designed for people like you: informed consumers who deserve honest education, not false promises. People who want to make their own decisions based on real science. People who need options when conventional medicine falls short.

Ready to explore? Visit OilWellCBD.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/ for complete product guide, science, competitive analysis, protocols, and ordering information.

Questions about shipping to Trinidad and Tobago? Call (832) 416-2816 or email [email protected]. We’ll walk you through customs documentation, legal verification, and delivery options.

Can’t afford our products? Use the formulas published here. Source the ingredients. Make your own. That’s why we published them. Bentley’s golden paste recipe is there for any pet owner facing crisis. RSO formulas are there for any person facing health crisis. That’s not marketing — that’s mission.

From Houston’s Montrose neighborhood to Trinidad and Tobago’s shores, from Bentley’s miracle to your own journey — OilWell Cannabis is here to provide the best possible version of cannabis education and products, so you can give it a fair shot and decide if it’s right or wrong for you.

Always consult local healthcare providers in Trinidad and Tobago before starting any cannabinoid regimen. Our products complement medical care; they do not replace it.